

# PEAKS: powerful software for peptide *de novo* sequencing by tandem mass spectrometry

Bin Ma<sup>1\*</sup>, Kaizhong Zhang<sup>1</sup>, Christopher Hendrie<sup>2</sup>, Chengzhi Liang<sup>2</sup>, Ming Li<sup>3</sup>, Amanda Doherty-Kirby<sup>4</sup> and Gilles Lajoie<sup>4</sup>

<sup>1</sup>Department of Computer Science, University of Western Ontario, London, ON N6A 5B7, Canada

<sup>2</sup>Bioinformatics Solutions Inc., Waterloo, ON N2L 3L2, Canada

<sup>3</sup>Department of Computer Science, University of Waterloo, Waterloo, ON N2L 3G1, Canada

<sup>4</sup>Department of Biochemistry, University of Western Ontario, London, ON N6A 5C1, Canada

Received 1 August 2003; Revised 21 August 2003; Accepted 21 August 2003

**A number of different approaches have been described to identify proteins from tandem mass spectrometry (MS/MS) data. The most common approaches rely on the available databases to match experimental MS/MS data. These methods suffer from several drawbacks and cannot be used for the identification of proteins from unknown genomes. In this communication, we describe a new *de novo* sequencing software package, PEAKS, to extract amino acid sequence information without the use of databases. PEAKS uses a new model and a new algorithm to efficiently compute the best peptide sequences whose fragment ions can best interpret the peaks in the MS/MS spectrum. The output of the software gives amino acid sequences with confidence scores for the entire sequences, as well as an additional novel positional scoring scheme for portions of the sequences. The performance of PEAKS is compared with Lutefisk, a well-known *de novo* sequencing software, using quadrupole-time-of-flight (Q-TOF) data obtained for several tryptic peptides from standard proteins. Copyright © 2003 John Wiley & Sons, Ltd.**

Tandem mass spectrometry (MS/MS) is emerging as the most reliable tool to identify proteins. There are now several configurations of mass spectrometers that provide MS/MS data with sufficient mass accuracy to deduce peptide sequences of enzymatically digested proteins from low-energy collisionally induced (CID) MS/MS spectra. However, deducing peptide sequences from raw MS/MS data is slow and tedious when performed manually. Instead, the most popular approach is to search databases of known genomes with the uninterpreted experimental MS/MS data. A number of such approaches have been described, the most popular being Mascot<sup>1</sup> and Sequest.<sup>2</sup> These methods are effective but often give false positives or incorrect identifications. Searching databases with masses and partial sequences (sequence tags) derived from MS/MS data give more reliable results.<sup>3</sup> For unknown genomes, *de novo* sequencing must be carried out in order to obtain sequences or partial sequences. Full sequences can then be obtained by cloning the gene of interest.

The deduction of amino acid sequences from MS/MS spectra is dependent on the quality of the data and further complicated by poor fragmentation and inaccuracies due to mass shifts caused by drifts in temperature and other

instrumental parameters. To aid the assignment of sequences a number of chemical techniques have been developed to favor the formation of more stable 'y' or 'b' ions.<sup>4,5</sup> Isotopic labeling introduced in the tryptic digestion step can also be used to identify 'y' ions.<sup>6</sup>

A number of algorithms and software packages have been reported for the deduction of protein sequences from MS/MS data.<sup>7–15</sup> Several instrument manufacturers have developed their own but these are in many cases unsatisfactory. One software package developed independently, Lutefisk, has gained a lot of attention.<sup>10,11</sup> Most of these software packages, including Lutefisk, use a graph theory approach. The spectrum is first translated into a 'spectrum graph' where nodes in the graph correspond to peaks in the spectrum and two nodes are connected by an edge if the mass difference between the two corresponding peaks is equal to the mass of an amino acid. The software then attempts to find a path that connects the N and C termini, and to connect all the nodes corresponding to the y ions (or b ions). In this paper we describe another approach with a new mathematical model and software, called PEAKS, for *de novo* sequencing of peptides from MS/MS data.

PEAKS performs *de novo* sequencing directly from the MS/MS data and therefore does not rely on a protein database. It computes the best possible sequence among all possible amino acid combinations. Analogous approaches have been described, but were computationally inefficient and abandoned.<sup>13–15</sup> Instead, PEAKS relies on a sophisticated dynamic programming algorithm to perform the

\*Correspondence to: B. Ma, Department of Computer Science, University of Western Ontario, London, ON N6A 5B7, Canada. E-mail: bma@csd.uwo.ca  
Contract/grant sponsors: NSERC; ORDCF; Bioinformatics Solutions Inc.

computation efficiently. The mathematical model that PEAKS uses is also different from the graph theory approach. In our approach, PEAKS computes peptides whose ions correspond to as many high abundance peaks in the spectrum as possible. We describe below the basic concepts behind this new PEAKS software, and compare its performance with experimental MS/MS data with that of Lutefisk, another available software tool for *de novo* sequencing.

## METHOD


The approach taken in PEAKS can be summarized into four steps: (1) preprocessing, (2) candidate computation, (3) refined scoring, and (4) global and positional confidence scoring. The first step consists of preprocessing of the raw MS/MS data. This involves a new method for noise filtering and peak centering, as well as deconvolution of the doubly and triply charged species to singly charged ions. This step is very important for the interpretation of MS/MS data by PEAKS. In fact we found a much higher success rate using raw data instead of using data preprocessed by various manufacturers' software. This indicates that optimal preprocessing of data is an important step for *de novo* sequencing by MS/MS.

The second step, candidate computation, is the critical step in which the 10 000 best sequences of all possible combinations of amino acids for a given precursor ion mass are computed. For this computation, the a, b, c, x, y and b/y-17/18 ions are considered. The basic assumption of our model is that the greater number of high abundance peaks that are matched by those ions of a sequence, the more likely the predicted sequence is the correct sequence. For each mass value  $m$ , this new algorithm first computes the reward/penalty that a y (or b) ion has mass  $m$ . If there is a peak close to  $m$ , the reward is equal to the logarithmic abundance of the peak multiplied by a factor reflecting the mass error between  $m$  and the mass value of the peak, and multiplied by a factor reflecting the co-existence of the x, y-H<sub>2</sub>O, y-NH<sub>3</sub> (or a, c, b-H<sub>2</sub>O, b-NH<sub>3</sub>) ions. If there is no peak close to  $m$ , the reward is a negative constant value. The problem is then reduced to finding a sequence such that its y and b ions maximize the total rewards at their mass values.

The initial mathematical formula used to compute the reward at mass was purely empirical, but has been refined. Because the PEAKS algorithm is highly modular, the modification or change of the formula for reward computation is relatively easy. In fact several formulas have been evaluated, but we found the following formula to be satisfactory for Q-TOF MS/MS and therefore it is used in PEAKS 1.3.

$$f\left(\frac{h_1}{h}\right) \times f\left(\frac{h_2}{h}\right) \times f\left(\frac{h_3}{h}\right) \times \exp\left(-\left(\frac{m' - m}{\delta}\right)^2\right) \times \log h \quad (1)$$

In Formula (1),  $m$  is the mass of a y-ion,  $m'$  is the mass of the observed peak for that y-ion, and  $\delta$  is the mass error tolerance of the spectrometer. Thus, the exponential factor in Formula (1) is designed to represent the mass error.  $h, h_1, h_2, h_3$ , denote the relative abundances of the observed y-ion peak and the



**Figure 1.** Curve of the supporting function  $y = f(x)$  in PEAKS 1.3.

corresponding x, y-H<sub>2</sub>O, y-NH<sub>3</sub> peaks ( $h_i = 0$  if the corresponding peak is not present). Thus, the logarithmic factor is designed to represent the relative abundance, and the functions  $f(\frac{h_i}{h})$  are designed to represent the presence of the x, y-H<sub>2</sub>O, y-NH<sub>3</sub> peaks (supporting peaks). The choice of the function  $f(x)$  was fairly arbitrary. Because we expect that the supporting peaks will have abundances comparable with that of the y-ion peak, in PEAKS 1.3, we chose  $f(x)$  to have the form of the curve shown in Fig. 1. Thus, the supporting factor is never less than 1, but is greater than 1 when  $h_i$  is comparable with  $h$ .

The rewards for b ions are computed in the same way as for y ions. The only difference is that we now have four supporting factors: a, c, b-H<sub>2</sub>O and b-NH<sub>3</sub>. Also, because y ions are usually more abundant than b ions for tryptic peptides on Q-TOF instruments, we multiply all the b-ion rewards by 0.5 to force the algorithm to use y ions first to explain the mass of the fragments.

Our approach to tabulating the total reward is very different from the spectrum graph model used by previous *de novo* sequencing software and algorithms. Because the spectrum graph model attempts to find a path connecting the N and C termini, the absence of ions may break such a path and makes difficult the completion of the sequence. However, in our approach, a reward/penalty score is computed for every possible mass value, regardless of the observation of a peak around that mass value. Therefore, the absence of peaks does not cause major problems. Also, the reward/penalty score accounts for many factors like the abundance of the peak, the mass errors and the co-existence of other peaks, all of which significantly improve the accuracy of the *de novo* sequencing results. A modified version of the recently published *de novo* sequencing algorithm using dynamic programming (Ma *et al.*<sup>16</sup>) is used in PEAKS to compute very efficiently the 10 000 sequences with the highest scores.

In the third step, each of the 10 000 candidates is re-evaluated by a more stringent scoring scheme, and the best candidates (the number can be specified by users) under the new scoring scheme will be outputted. In this refined rescoring step, ion mass error tolerance is stricter. The rewards for immonium ions as well as internal cleavage ions are now considered. The reward/penalty computation is the same as for y and b ions. The immonium and internal cleavage ions are not accounted for in the second step because their inclusion would be too computationally inefficient to

derive the best 10 000 candidates. Finally, a recalibration of the data is performed to account for minor deviations in the MS/MS data. This recalibration method is similar to that described by Taylor *et al.*<sup>11</sup>

In the last step, PEAKS computes a confidence score for each of the top-scoring peptide sequences. The refined scores can be seen as non-normalized measures of the likelihood of correctness for each peptide, and the distribution of scores gives a measure of the overall probability of successful sequencing. PEAKS first converts the refined score  $x$  of each peptide sequence to a raw confidence  $X$  by the formula  $X = \exp(cx)$ , where  $c$  is a parameter that is estimated from the spectrum by PEAKS. Then the raw confidence scores for all the top-scoring peptide sequences are normalized to be the final confidence scores so that they sum up to 1. Finally, the positional confidences for each residue are derived from consensus among the globally top-scoring sequences.

### INPUT and OUTPUT for PEAKS

PEAKS can read MS/MS spectra in several different formats including Micromass .pkl files, Sequest .dta files, and Mascot Generic Format (.mgf) files. Data from other manufacturers can be inputted as text files. For each spectrum, PEAKS outputs a list of amino acid sequences that can possibly generate the MS/MS spectrum, from the most to the least likely sequence. The default number of output sequences in the list is five and can be changed by the user. PEAKS also associates each output sequence with a confidence level. The confidence level is a percentage number between 0 and 100%, indicating how likely the complete sequence is correct.

PEAKS also outputs a confidence level for each individual amino acid in the sequence using different colors. In the current version, an amino acid (one letter code) colored red indicates a 95% confidence to be correct, green correspond to 90–95%, blue 80–90%, and black less than 80%. (In this manuscript, bold fonts are used to indicate the red, green and blue colors.) This unique feature allows a user to obtain very high confidence sequence tags, even in cases where PEAKS cannot find the complete sequence with a high confidence level due to poor quality of the experimental data.

### EXPERIMENTAL RESULTS

The internal parameters of PEAKS were initially adjusted using MS/MS data from known proteins. A blind test was then used to evaluate the performance of the *de novo* sequencing of PEAKS. MS/MS data were obtained from Q-TOF2 and Q-TOF-Global mass spectrometers (Micromass, UK) for four standard proteins, purchased from Sigma and digested in solution with trypsin. These proteins were alcohol dehydrogenase (yeast), myoglobin (horse), albumin (bovine, BSA), and cytochrome C (horse). The results reported here were obtained with PEAKS version 1.3. The PEAKS software can be used on-line free of charge.<sup>17</sup> The *de novo* sequencing software Lutefisk<sup>11</sup> was used as a comparison for the same set of data. Lutefisk was graciously provided by one of its authors through e-mail contact.

For each protein, a collated data file of the MS/MS spectra was obtained as follows. For each precursor mass, the corresponding scans were combined automatically using


the PeptideAuto.exe function of MassLynx 3.5 (Micromass). The peak list of this summed spectrum was copied using the Edit, Copy Spectrum List function of Masslynx 3.5 into Notepad. The precursor  $m/z$  was added at the very beginning of each peak list in the text file using the following format:  $m/z$  0.000 z. The resulting text file then contains several peptide spectra for each protein. If the precursor ion masses of two spectra in the same file differ by no more than 0.05 Da, then the two spectra are merged into one MS/MS spectrum by putting the two peak lists into one. Next, a simple criterion is applied to remove the poor quality spectra as follows.

For an MS/MS spectrum, we define the *average signal intensity* as  $s/m$ , where  $s$  is the sum of the abundances of the peaks higher than 2 (peaks lower than 2 cannot be distinguished from noise), and  $m$  is the peptide mass (which is equal to the precursor ion mass minus the protons).  $s$  is divided by  $m$  because peptides with higher masses are generally longer and therefore the larger number of fragments give more total signal intensity. Thus, for larger peptides, higher total signal intensity is required for the *de novo* sequencing. Visual inspection revealed that the quality of the spectra with average signal intensity lower than 0.6 is generally very poor. Hence, the spectra whose average signal intensity was lower than 0.6 were removed from the raw data files. Figure 2 shows an example of an excluded spectrum with average signal intensity 0.56, and Fig. 3 shows an example of a retained spectrum (the precursor ion at  $m/z$  675.72 in the albumin data set) with average signal intensity of 0.7. As given in Table 1, PEAKS computed a correct partial sequence of nine consecutive amino acids for the MS/MS spectrum in Fig. 3.


After this initial sorting, the remaining data contain 54 spectra from tryptic digestions (C-terminus is either R or K) and four spectra from non-tryptic digestions (C-terminus is not R or K). The average signal intensities for the four spectra from non-tryptic digestions are 21.5, 4.7, 1.0 and 0.9, respectively. PEAKS deduced partially correct sequences of length 7, 4, 4, and 2 amino acids, respectively. This suggests that PEAKS requires high-quality spectra for *de novo* sequencing of non-tryptic spectra. Lutefisk, however, did not find any sequences for these four spectra.

Both PEAKS and Lutefisk were then used to compute the sequences of the 54 MS/MS spectra *de novo*. Although both software packages output several results for each spectrum, we selected here only the first result (with the highest score) among their outputs. Table 1 summarizes the results obtained by PEAKS and Lutefisk for BSA MS/MS spectra. The underlined amino acids are those correctly computed by PEAKS or Lutefisk (no distinction between the amino acids L with I, and K with Q). The bold-font amino acids (one letter code) in the PEAKS computation indicate that PEAKS gave confidence scores  $\geq 80\%$  for those amino acids. The computed sequences of the other three proteins are not given here but can be found on the Internet.<sup>18</sup> The 54 MS/MS spectra are also available at the same web site.

For the 54 MS/MS spectra, Table 2 gives the numbers of sequences that PEAKS and Lutefisk computed completely or partially correctly (with at least six consecutively correct amino acids). It can be seen that PEAKS performed better than Lutefisk on these 54 spectra. It is important to note that



**Figure 2.** Spectrum of poor quality with average signal intensity of 0.56 not selected for analysis.



**Figure 3.** Spectrum from BSA digestion (precursor ion 675.72) of acceptable quality with average signal intensity of 0.7 and selected for analysis.

**Table 1.** Performance of PEAKS and Lutfisk on albumin (bovine) MS/MS data set. The spectrum quality column (s/m) shows the average signal intensity of each spectrum

<i>m/z</i>	<i>z</i>	Correct	PEAKS	Lutfisk	s/m
Albumin					
417.21	3	FKDLGEEHFK	RLCMGEEHFK	No quality sequence found	5.1
454.88	3	SLHTLFGDELCK	TVHTLFGDELCK	No quality sequence found	4.3
461.72	2	AEFVEVTK	AEFVEPCK	[200.08]FVEVTK	61.1
464.24	2	YLYEIAR	YLYELAR	YLYELAR	45.8
465.77	2	LKAWSVAR	LKAWSVAR	LKAWSVAR	2.1
473.58	3	LKECCDKP LLEK	RTLCCDKP LLEK	No quality sequence found	9.9
501.29	2	ALKAWSVAR	LAKAWSVAR	[184.12]KAWWAR	2.3
507.79	2	QTALVELLK	GATALVELLK	[229.11]ALVELLK	5.8
515.79	4	YTRKVPQVSTPTLVEVSR	WHYEHFTDKNLVEVSR	[200.08][244.07][LP][AH]RP[242.14]LVEVSR	2.5
547.26	3	KVPQVSTPTLVEVSR	KVAPGVSTPTLVEVSR	No quality sequence found	93.2
571.86	2	KQTALVELLK	KQTALVELLK	KQTALVELLK	1.8
582.29	2	LVNELTEFAK	LVNELTEFAK	LVNELTEFAK	11.7
642.36	2	HPEYAVSVLLR	HPEYAVPSDLR	No quality sequence found	1.1
653.38	2	HLVDEPQNLIK	HLVDEPKNLLK	HLVDE[225.15]NLLK	7.8
675.72	3	KVPQVSTPTLVEVSRSLGK	KVNPLGMHCAVEVSRSLGK	No quality sequence found	0.7
681.84	2	SLHTLFGDELCK	SLHTLFGDELCK	[HT]VTL[GV]YE[216.07]K	2.5
693.80	2	YICDNQDTISSK	YLCDNQDTLSSK	YL[218.07]NQDTLSSK	22.1
740.39	2	LGEYGFQNALIVR	LGEYGFQNALIVR	LWYGFQNALIVR	17.9
756.42	2	VPQVSTPTLVEVSR	VPQVSTPNAKEVSR	No quality sequence found	1.3
767.70	3	NYQEAKDAFLGSFLYEYSR	QHSSFVHTAQGGSFLYEYSR	[276.11]GK[SS][MT][199.10]LGSFLYEYSR	2.1
784.34	2	DAFLGSFLYEYSR	WFLGSFLATAAGGNR	[186.07]FLGSFLYEYSR	15.9
820.45	2	KVPQVSTPTLVEVSR	KVPQVSTMAHADEVSR	No quality sequence found	2.7
824.74	3	QNCDQFEKLGEYGFQNALIVR	QLSEMFELKLWYGFQNALIVR	No quality sequence found	0.9

**Table 2.** Number of completely or partially correct sequences computed by PEAKS and Lutefisk

Spectrum quality (s/m)	Total number of spectra	Completely correct sequences		Sequences with six consecutively correct amino acids	
		PEAKS	Lutefisk	PEAKS	Lutefisk
>10	27	13 (48%)	8 (30%)	25 (93%)	18 (67%)
0.6–10	27	9 (33%)	3 (11%)	26 (96%)	9 (33%)
Overall	54	22 (41%)	11 (20%)	51 (94%)	27 (50%)

**Table 3.** Number of correct amino acids computed by PEAKS and Lutefisk


Spectrum quality (s/m)	Total number of amino acids	PEAKS	Lutefisk
>10	307	262 (85%)	185 (60%)
0.6–10	341	261 (77%)	122 (36%)
Overall	648	523 (81%)	307 (47%)

for the 27 spectra of lower quality (s/m between 0.6 and 10), PEAKS computed three times as many completely or partially correct sequences as Lutefisk.

Table 3 gives the total number of correct amino acids that PEAKS and Lutefisk computed. From this table it is also evident that PEAKS performed better than Lutefisk. For spectra with lower quality (0.6–10), PEAKS computed more than twice as many correct amino acids as Lutefisk.

PEAKS gives a positional confidence score to individual amino acids that it assigns. The amino acids to which PEAKS give high confidence are usually the correct amino acids, but PEAKS occasionally makes mistakes. It is also possible that PEAKS computes some correct amino acids but assigns low confidence. Figure 4 illustrates for the 54 spectra the relationship between the amino acids to which PEAKS gave a high confidence score ( $\geq 80\%$ ) and those that PEAKS assigned correctly. The figure illustrates that PEAKS positional confidence scoring is fairly reliable: 92% ( $= 484 / (41 + 484)$ ) of the amino acids that were given high ( $\geq 80\%$ ) confidence are correct, and 93% ( $= 484 / (39 + 484)$ ) of the amino acids that were computed correctly have high ( $\geq 80\%$ ) confidence.

Both PEAKS and Lutefisk can compute the MS/MS data rapidly. On average, they process each MS/MS spectrum in a few seconds on a Pentium 1GHz PC. PEAKS (including its interface) requires 512 M bytes of memory, common to most desktop computers currently available. We do not know

**Figure 4.** Relationship between the amino acids for which PEAKS gave a high confidence score ( $\geq 80\%$ ) and the amino acids that PEAKS computed correctly.

Lutefisk's memory requirement but it can be run with no problems on a PC with 512 M bytes of memory.

Finally, we want to point out that all of the amino acids wrongly assigned by PEAKS were caused by mass equivalence. Some examples in Table 2 are: mass(SL) = mass(TV) in precursor 454.88, mass(VT) = mass(PC) in precursor 461.72, mass(AL) = mass(LA) in precursor 501.29, and mass(Q) = mass(GA) in precursor 507.79. If the correct sequence is in a database and the computed sequence is partially correct, this type of error can usually be overcome by a careful database search with the sequences. For example, one software system, SPIDER,<sup>19</sup> can be fed with sequences containing *de novo* sequencing errors but find the correct sequences in the database.

## CONCLUSIONS

From this initial evaluation, we can see that PEAKS performs very well for *de novo* sequencing of Q-TOF spectra compared with Lutefisk. PEAKS also performed better than other *de novo* sequencing software from manufacturers of mass spectrometers (data not shown). Not only does PEAKS compute more correct sequences and amino acids than the other software, but also it outputs positional confidence scores, which reliably determine which sequences or amino acids are correct. Although not discussed here, PEAKS has already been used to successfully compute the peptides with some common post-translational modifications. Future versions will include the ability to compute a wider range of more complex modifications. PEAKS should be a very useful tool for the analysis of proteomes of both known and unknown genomes.

## Acknowledgements

This work was supported by NSERC research grants to BM and KZ, and by the Ontario Research and Development Challenge Fund (ORDCF) to GL and by Bioinformatics Solutions Inc. (Waterloo, ON, Canada). We also thank Dr. R. Johnson for kindly providing the Lutefisk software.

## REFERENCES

- Perkins DN, Pappin DJC, Creasy DM, Cottrell JS. *Electrophoresis* 1999; **20**: 3551.
- Eng JK, McCormack AL, Yates JR III. *J. Am. Soc. Mass Spectrom.* 1994; **5**: 976.
- Mann M, Wilm M. *Anal. Chem.* 1994; **66**: 4390.
- Keough T, Lacey MP, Youngquist RS. *Rapid Commun. Mass Spectrom.* 2000; **14**: 2348.
- Munchbach M, Quadroni M, Miotto G, James P. *Anal. Chem.* 2000; **72**: 4047.

6. Uttenweiler-Joseph S, Neubauer G, Christoforidis S, Zerial M, Wilm M. *Proteomics* 2001; **1**: 668.
7. Bartels C. *Biomed. Environ. Mass Spectrom.* 1990; **19**: 363.
8. Chen T, Kao M, Tepel M, Rush J, Church G. *J. Comput. Biol.* 2001; **8**: 325.
9. Dančík V, Addona T, Clauser K, Vath J, Pevzner P. *J. Comput. Biol.* 1999; **6**: 327.
10. Taylor JA, Johnson RS. *Rapid Commun. Mass Spectrom.* 1997; **11**: 1067.
11. Taylor JA, Johnson RS. *Anal. Chem.* 2001; **73**: 2594.
12. Fernández de Cossío J, Gonzales J, Besada V. *CABIOS* 1995; **1**: 427.
13. Hamm CW, Wilson WE, Harvan DJ. *CABIOS* 1986; **2**: 115.
14. Hines WM, Falick AM, Burlingame AL, Gibson BW. *J. Am. Soc. Mass Spectrom.* 1992; **3**: 326.
15. Sakurai T, Matsuo T, Matsuda H, Katakuse I. *Biomed. Mass Spectrom.* 1984; **11**: 396.
16. Ma B, Zhang K, Liang C. *Symp. Comb. Pattern Matching* 2003; 266.
17. Available: <http://www.bioinformaticssolutions.com>.
18. Available: <http://www.csd.uwo.ca/~bma/peaks/>.
19. Han Y, Ma B, Zhang K. Unpublished. Available: <http://proteome.sharcnet.ca:8080/spider/>.